Emergent BioSolutions, Inc. (EBS)
5.505
-0.10
(-1.87%)
USD |
NYSE |
Nov 18, 16:00
5.505
0.00 (0.00%)
After-Hours: 20:00
Emergent BioSolutions Enterprise Value : 624.59M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 624.59M |
| November 16, 2026 | 634.85M |
| November 13, 2026 | 633.83M |
| November 12, 2026 | 638.96M |
| November 11, 2026 | 646.65M |
| November 10, 2026 | 647.16M |
| November 09, 2026 | 649.73M |
| November 06, 2026 | 647.68M |
| November 05, 2026 | 636.90M |
| November 04, 2026 | 639.47M |
| November 03, 2026 | 657.42M |
| November 02, 2026 | 667.17M |
| October 30, 2026 | 686.15M |
| October 29, 2026 | 707.19M |
| October 28, 2026 | 700.52M |
| October 27, 2026 | 678.97M |
| October 26, 2026 | 662.04M |
| October 23, 2026 | 656.40M |
| October 22, 2026 | 656.40M |
| October 21, 2026 | 654.86M |
| October 20, 2026 | 659.48M |
| October 19, 2026 | 663.07M |
| October 16, 2026 | 664.09M |
| October 15, 2026 | 705.13M |
| October 14, 2026 | 691.28M |
| Date | Value |
|---|---|
| October 13, 2026 | 691.28M |
| October 12, 2026 | 694.87M |
| October 09, 2026 | 698.98M |
| October 08, 2026 | 686.15M |
| October 07, 2026 | 699.49M |
| October 06, 2026 | 693.34M |
| October 05, 2026 | 708.21M |
| October 02, 2026 | 661.53M |
| October 01, 2026 | 663.58M |
| September 30, 2026 | 675.38M |
| September 29, 2026 | 802.30M |
| September 28, 2026 | 799.22M |
| September 25, 2026 | 795.63M |
| September 24, 2026 | 794.60M |
| September 23, 2026 | 789.47M |
| September 22, 2026 | 794.09M |
| September 21, 2026 | 783.32M |
| September 18, 2026 | 796.14M |
| September 17, 2026 | 807.43M |
| September 16, 2026 | 793.58M |
| September 15, 2026 | 773.57M |
| September 14, 2026 | 774.59M |
| September 11, 2026 | 766.90M |
| September 10, 2026 | 748.43M |
| September 09, 2026 | 738.68M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals, Inc. | 135.60B |
| Arcturus Therapeutics Holdings, Inc. | 63.88M |
| Capricor Therapeutics, Inc. | 383.60M |
| Travere Therapeutics, Inc. | 5.033B |
| Syndax Pharmaceuticals, Inc. | 990.21M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.70M |
| Revenue (Quarterly) | 110.00M |
| Total Expenses (Quarterly) | 142.70M |
| EPS Diluted (Quarterly) | -0.6374 |
| Gross Profit Margin (Quarterly) | 18.09% |
| Profit Margin (Quarterly) | -29.73% |
| Earnings Yield | -92.59% |
| Operating Earnings Yield | 11.01% |
| Normalized Earnings Yield | -36.69 |